SCVRH LLC

SCVRH LLC was paid $2.84M by Medicaid between Apr 2019 and Jun 2022, across 77 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 33% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2019	11,629	$375K
2020	21,845	$1.10M
2021	22,588	$936K
2022	9,492	$432K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	33%	7,596	7,073	$950K
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	26%	1,941	1,654	$726K
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	20%	2,374	2,166	$577K
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	8.6%	1,583	1,488	$245K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	5.0%	1,871	1,788	$143K
74177	Computed tomography, abdomen and pelvis; with contrast material	3.6%	591	537	$103K
G0378	Hospital observation service, per hour	<1%	47	39	$26K
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	<1%	35	31	$18K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	644	196	$12K
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	<1%	621	228	$11K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	1,338	1,228	$11K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	60	57	$7K

65 more codes

93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	1,495	$3K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	444	$2K
96376		<1%	126	$2K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	121	$2K
99281	Emergency department visit for the evaluation and management, self-limited or minor	<1%	27	$1K
84443	Thyroid stimulating hormone (TSH)	<1%	121	$1K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	9,340	$908.54
96361	Intravenous infusion, hydration; each additional hour	<1%	1,039	$738.29
80053	Comprehensive metabolic panel	<1%	3,379	$703.00
71045	Radiologic examination, chest; single view	<1%	1,558	$541.68
70450	Computed tomography, head or brain; without contrast material	<1%	389	$438.77
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	1,002	$431.44
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	106	$384.62
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	1,873	$315.52
71046	Radiologic examination, chest; 2 views	<1%	132	$202.93
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	1,119	$170.20
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	3,907	$168.40
84484		<1%	1,500	$151.90
36415	Collection of venous blood by venipuncture	<1%	320	$151.50
96375	Therapeutic injection; each additional sequential IV push	<1%	1,554	$133.45
83880		<1%	159	$128.07
83735		<1%	1,994	$68.25
81001		<1%	1,469	$49.10
85610		<1%	1,203	$45.39
85730		<1%	898	$45.01
83690		<1%	1,345	$43.76
87186		<1%	77	$27.97
80048	Basic metabolic panel (calcium, ionized)	<1%	521	$27.69
81025		<1%	791	$23.86
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	345	$23.53
87086	Culture, bacterial; quantitative colony count, urine	<1%	572	$21.80
85379		<1%	198	$19.26
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	417	$17.70
87081		<1%	274	$16.58
80306		<1%	243	$15.96
84702		<1%	14	$15.12
83605		<1%	607	$10.34
81003		<1%	690	$10.34
82962		<1%	316	$5.36
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	136	$5.25
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	327	$4.88
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	1,243	$4.55
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	<1%	461	$0.32
J2550	Injection, promethazine hcl, up to 50 mg	<1%	44	$0.23
J2765	Injection, metoclopramide hcl, up to 10 mg	0%	95	$0.00
J1170	Injection, hydromorphone, up to 4 mg	0%	134	$0.00
A9270	Non-covered item or service	0%	555	$0.00
J2704	Injection, propofol, 10 mg	0%	280	$0.00
J3490	Unclassified drugs	0%	268	$0.00
J1885	Injection, ketorolac tromethamine, per 15 mg	0%	257	$0.00
J0696	Injection, ceftriaxone sodium, per 250 mg	0%	190	$0.00
88305	Level IV - Surgical pathology, gross and microscopic examination	0%	35	$0.00
97016		0%	127	$0.00
86901		0%	14	$0.00
J2060	Injection, lorazepam, 2 mg	0%	14	$0.00
J2250	Injection, midazolam hydrochloride, per 1 mg	0%	14	$0.00
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	0%	15	$0.00
J2270	Injection, morphine sulfate, up to 10 mg	0%	319	$0.00
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	0%	281	$0.00
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	0%	63	$0.00
J7030	Infusion, normal saline solution , 1000 cc	0%	243	$0.00
84100		0%	14	$0.00
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	0%	12	$0.00
86900		0%	14	$0.00
J3475	Injection, magnesium sulfate, per 500 mg	0%	13	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialZIEGELE, PAUL (CFO)